Full Press Release Details
New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China.
SGMT
New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China
Key Takeaway: New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease